These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 30383134)

  • 1. On-Demand Sildenafil as a Treatment for Raynaud Phenomenon: A Series of n-of-1 Trials.
    Roustit M; Giai J; Gaget O; Khouri C; Mouhib M; Lotito A; Blaise S; Seinturier C; Subtil F; Paris A; Cracowski C; Imbert B; Carpentier P; Vohra S; Cracowski JL
    Ann Intern Med; 2018 Nov; 169(10):694-703. PubMed ID: 30383134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial.
    Vizza CD; Jansa P; Teal S; Dombi T; Zhou D
    BMC Cardiovasc Disord; 2017 Sep; 17(1):239. PubMed ID: 28874133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis.
    Herrick AL; van den Hoogen F; Gabrielli A; Tamimi N; Reid C; O'Connell D; Vázquez-Abad MD; Denton CP
    Arthritis Rheum; 2011 Mar; 63(3):775-82. PubMed ID: 21360507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, Multicenter Study to Assess the Effects of Different Doses of Sildenafil on Mortality in Adults With Pulmonary Arterial Hypertension.
    Hoeper MM; Ewert R; Jansa P; Sirenko Y; Skride A; Balagtas C; Hackley S; Vogt S; Abreu P; Haughie S; Hassan T; Oudiz RJ
    Circulation; 2024 Jun; 149(25):1949-1959. PubMed ID: 38752352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detailed statistical analysis plan for the Dutch STRIDER (Sildenafil TheRapy In Dismal prognosis Early-onset fetal growth Restriction) randomised clinical trial on sildenafil versus placebo for pregnant women with severe early onset fetal growth restriction.
    Pels A; Jakobsen JC; Ganzevoort W; Naaktgeboren CA; Onland W; van Wassenaer-Leemhuis AG; Gluud C
    Trials; 2019 Jan; 20(1):42. PubMed ID: 30635020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sildenafil's effectiveness in the primary coronary slow flow phenomenon: a pilot randomised controlled clinical trial.
    Andishmand A; Seyedhosseini S; Namayandeh SM; Adelzadeh E; Entezari A; Mirjalili SR
    Open Heart; 2024 Aug; 11(2):. PubMed ID: 39214536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nifedipine cream versus sildenafil cream for patients with secondary Raynaud phenomenon: A randomized, double-blind, controlled pilot study.
    Wortsman X; Del Barrio-Díaz P; Meza-Romero R; Poehls-Risco C; Vera-Kellet C
    J Am Acad Dermatol; 2018 Jan; 78(1):189-190. PubMed ID: 29241781
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety of topical sildenafil cream, 3.6% in a randomized, placebo-controlled trial for the treatment of female sexual arousal disorder.
    Thurman AR; Johnson I; Cornell KA; Hatheway J; Kim NN; Parish SJ; Dart C; Friend DR; Goldstein A
    J Sex Med; 2024 Sep; 21(9):793-799. PubMed ID: 39079074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nightly vs on-demand sildenafil for penile rehabilitation after minimally invasive nerve-sparing radical prostatectomy: results of a randomized double-blind trial with placebo.
    Pavlovich CP; Levinson AW; Su LM; Mettee LZ; Feng Z; Bivalacqua TJ; Trock BJ
    BJU Int; 2013 Oct; 112(6):844-51. PubMed ID: 23937708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy with Bosentan and Sildenafil improves Raynaud's phenomenon and fosters the recovery of microvascular involvement in systemic sclerosis.
    Bellando-Randone S; Lepri G; Bruni C; Blagojevic J; Radicati A; Cometi L; De Paulis A; Matucci-Cerinic M; Guiducci S
    Clin Rheumatol; 2016 Jan; 35(1):127-32. PubMed ID: 26631100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective, randomized, placebo-controlled trial of on-Demand vs. nightly sildenafil citrate as assessed by Rigiscan and the international index of erectile function.
    Kim DJ; Hawksworth DJ; Hurwitz LM; Cullen J; Rosner IL; Lue TF; Dean RC
    Andrology; 2016 Jan; 4(1):27-32. PubMed ID: 26663669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Head-to-head comparison of udenafil vs amlodipine in the treatment of secondary Raynaud's phenomenon: a double-blind, randomized, cross-over study.
    Lee EY; Park JK; Lee W; Kim YK; Park CS; Giles JT; Park JW; Shin K; Lee JS; Song YW; Lee EB
    Rheumatology (Oxford); 2014 Apr; 53(4):658-64. PubMed ID: 24352340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sildenafil increases digital skin blood flow during all phases of local cooling in primary Raynaud's phenomenon.
    Roustit M; Hellmann M; Cracowski C; Blaise S; Cracowski JL
    Clin Pharmacol Ther; 2012 May; 91(5):813-9. PubMed ID: 22453196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
    Fries R; Shariat K; von Wilmowsky H; Böhm M
    Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials.
    Roustit M; Blaise S; Allanore Y; Carpentier PH; Caglayan E; Cracowski JL
    Ann Rheum Dis; 2013 Oct; 72(10):1696-9. PubMed ID: 23426043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
    Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
    Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrovascular Effects of Sildenafil in Small Vessel Disease: The OxHARP Trial.
    Webb AJS; Birks JS; Feakins KA; Lawson A; Dawson J; Rothman AMK; Werring DJ; Llwyd O; Stewart CR; Thomas J
    Circ Res; 2024 Jul; 135(2):320-331. PubMed ID: 38832504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the effect of sildenafil on the microvascular blood flow in patients with systemic sclerosis: a randomised, double-blind, placebo-controlled study.
    Andrigueti FV; Ebbing PCC; Arismendi MI; Kayser C
    Clin Exp Rheumatol; 2017; 35 Suppl 106(4):151-158. PubMed ID: 28281457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sildenafil improves vascular endothelial function in patients with cystic fibrosis.
    Rodriguez-Miguelez P; Lee N; Tucker MA; Csányi G; McKie KT; Forseen C; Harris RA
    Am J Physiol Heart Circ Physiol; 2018 Nov; 315(5):H1486-H1494. PubMed ID: 30168731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist.
    Webb DJ; Freestone S; Allen MJ; Muirhead GJ
    Am J Cardiol; 1999 Mar; 83(5A):21C-28C. PubMed ID: 10078539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.